Ron Peltier, HomeServices of America CEO, says the housing market is "normalizing" but the mortgage process is not rational. We have to bring common sense back into the marketplace, says Peltier.
John Rogers, Ariel Investments chairman & CEO, say there is plenty of buying opportunity in a volatile market.
Tributes pour in for Christophe de Margerie after the chief executive of Total died in a business jet crash in Moscow.
Tinder CEO Sean Rad, discusses how the Tinder app helps reduce the friction of two strangers meeting.
Omega Advisors' Leon Cooperman, discusses his firm's current position in Apple.
Omega Advisors' Leon Cooperman, explains why his firm still likes Monitise.
Omega Advisors' Leon Cooperman, discusses his take on the energy sector and low oil prices.
Omega Advisors' Leon Cooperman analyzes current economic data, saying he expects the market to end the year higher than it is today.
Omega Advisors' Leon Cooperman discusses the health of the current economic expansion. He explains why he thinks the multiple will be constrained on the market.
Omega Advisors' Leon Cooperman analyzes the current market environment, and outlines the top economic red flags for investors right now.
CNBC's Jon Fortt speaks to Microsoft CEO Satya Nadella about comments on compensation for women in the workplace, and what he can do to fix the disparity.
IBM Chairman and CEO Ginni Rometty, discusses the company's efforts to create long-term shareholder value.
Discussing the unique role IBM can play in the cloud industry, with IBM Chairman and CEO Ginni Rometty.
IBM Chairman and CEO Ginni Rometty, breaks down the quarterly earnings miss at the company, including for hardware and services sales.
CNBC's David Faber speaks to IBM Chairman and CEO Ginni Rometty, about the company's quarterly miss and transformation happening at the company.
CNBC's Jon Fortt spoke to Microsoft CEO Satya Nadella, about spinoffs in the tech industry. Jim Cramer, weighs in.
Michael Pearson, Valeant Pharmaceuticals CEO, shares his thoughts on allegations Allergan released false and misleading information.
Michael Pearson, Valeant Pharmaceuticals CEO, breaks down the company's quarterly numbers and provides an outlook on future growth.
At the start of the year, it looked like the pharma M&A market would get an adrenaline injection – but now, it's more like it’s taken a sleeping pill.